UY33277A - Compuestos de anillo espiro-tetraciclico como moduladores de beta-secretasa y métodos de uso - Google Patents
Compuestos de anillo espiro-tetraciclico como moduladores de beta-secretasa y métodos de usoInfo
- Publication number
- UY33277A UY33277A UY0001033277A UY33277A UY33277A UY 33277 A UY33277 A UY 33277A UY 0001033277 A UY0001033277 A UY 0001033277A UY 33277 A UY33277 A UY 33277A UY 33277 A UY33277 A UY 33277A
- Authority
- UY
- Uruguay
- Prior art keywords
- methods
- spiro
- beta
- ring compounds
- tetraciclic
- Prior art date
Links
- 102000002659 Amyloid Precursor Protein Secretases Human genes 0.000 title abstract 2
- 108010043324 Amyloid Precursor Protein Secretases Proteins 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 title abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 210000004556 brain Anatomy 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000007505 plaque formation Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
- C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
- C07D221/20—Spiro-condensed ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/08—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
- C07D295/135—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/20—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
- C09B—ORGANIC DYES OR CLOSELY-RELATED COMPOUNDS FOR PRODUCING DYES, e.g. PIGMENTS; MORDANTS; LAKES
- C09B11/00—Diaryl- or thriarylmethane dyes
- C09B11/28—Pyronines ; Xanthon, thioxanthon, selenoxanthan, telluroxanthon dyes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
Abstract
Compuestos de anillo espiro-tetracíclicos, farmacéuticamente activos, composiciones farmacéuticas y métodos de uso de los mismos, para tratar enfermedades mediadas por Beta-Secretasa y condiciones, que incluyen, sin limitación, enfermedad de Alzheimer, formación de placa en el cerebro y trastornos relacionados.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US31412910P | 2010-03-15 | 2010-03-15 |
Publications (1)
Publication Number | Publication Date |
---|---|
UY33277A true UY33277A (es) | 2011-09-30 |
Family
ID=43858320
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
UY0001033277A UY33277A (es) | 2010-03-15 | 2011-03-15 | Compuestos de anillo espiro-tetraciclico como moduladores de beta-secretasa y métodos de uso |
Country Status (10)
Country | Link |
---|---|
US (1) | US8883782B2 (es) |
EP (1) | EP2547685A1 (es) |
JP (1) | JP2013522305A (es) |
AR (1) | AR080524A1 (es) |
AU (1) | AU2011227511B2 (es) |
CA (1) | CA2791281A1 (es) |
MX (1) | MX2012010658A (es) |
TW (1) | TW201144322A (es) |
UY (1) | UY33277A (es) |
WO (1) | WO2011115938A1 (es) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7763609B2 (en) | 2003-12-15 | 2010-07-27 | Schering Corporation | Heterocyclic aspartyl protease inhibitors |
UA108363C2 (uk) | 2009-10-08 | 2015-04-27 | Похідні імінотіадіазиндіоксиду як інгібітори bace, композиція на їх основі і їх застосування | |
MX2012010657A (es) * | 2010-03-15 | 2013-02-07 | Amgen Inc | Compuestos de espiro amino-dihidrooxazina y amino-dihidrotiazina como moduladores de beta-secretasa y su uso medico. |
EP2643325A1 (en) | 2010-11-23 | 2013-10-02 | Amgen Inc. | Spiro-amino-imidazolone and spiro-amino-dihydro-pyrimidinone compounds as beta-secretase modulators and methods of use |
US9346827B2 (en) | 2011-02-07 | 2016-05-24 | Amgen Inc. | 5-amino-oxazepine and 5-amino-thiazepane compounds as beta secretase antagonists and methods of use |
EP2694489B1 (en) | 2011-04-07 | 2017-09-06 | Merck Sharp & Dohme Corp. | C5-c6 oxacyclic-fused thiadiazine dioxide compounds as bace inhibitors, compositions, and their use |
EP2694521B1 (en) | 2011-04-07 | 2015-11-25 | Merck Sharp & Dohme Corp. | Pyrrolidine-fused thiadiazine dioxide compounds as bace inhibitors, compositions, and their use |
WO2013028670A1 (en) | 2011-08-22 | 2013-02-28 | Merck Sharp & Dohme Corp. | 2-spiro-substituted iminothiazines and their mono-and dioxides as bace inhibitors, compositions and their use |
EP2758406A1 (en) | 2011-09-21 | 2014-07-30 | Amgen Inc. | Amino-oxazines and amino-dihydrothiazine compounds as beta-secretase modulators and methods of use |
JP5923823B2 (ja) | 2012-02-16 | 2016-05-25 | 国立大学法人広島大学 | アセンジカルコゲノフェン誘導体用中間体及びその合成方法 |
WO2013148851A1 (en) * | 2012-03-27 | 2013-10-03 | Array Biopharma Inc. | Compounds for treating neurodegenerative diseases |
EP2650284A1 (en) * | 2012-04-10 | 2013-10-16 | Merz Pharma GmbH & Co. KGaA | Heterocyclic derivatives as metabotropic glutamate receptor modulators |
CN104394862A (zh) | 2012-05-30 | 2015-03-04 | 科门蒂斯公司 | 色满化合物 |
US9725469B2 (en) | 2012-11-15 | 2017-08-08 | Amgen, Inc. | Amino-oxazine and amino-dihydrothiazine compounds as beta-secretase modulators and methods of use |
LT2953931T (lt) | 2013-01-31 | 2017-07-25 | Vertex Pharmaceuticals Incorporated | Piridono amidai kaip natrio kanalų moduliatoriai |
TW201437211A (zh) * | 2013-03-01 | 2014-10-01 | Bayer Pharma AG | 經取代咪唑并嗒□ |
CN104829414B (zh) * | 2015-04-24 | 2017-01-18 | 大连奇凯医药科技有限公司 | 1‑溴‑2‑氯‑3‑氟‑4‑碘苯的合成方法 |
Family Cites Families (79)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2683718A (en) | 1952-01-11 | 1954-07-13 | Searle & Co | Spiro-[xanthene-9, 4'-imidazolidine]-2, 5-dione |
US3185696A (en) * | 1959-03-12 | 1965-05-25 | Jack M Tien | 3', 6'-diaminofluoran derivatives of gamma-lactam |
US5441870A (en) | 1992-04-15 | 1995-08-15 | Athena Neurosciences, Inc. | Methods for monitoring cellular processing of β-amyloid precursor protein |
SI9300303A (en) | 1993-06-08 | 1994-12-31 | Krka Tovarna Zdravil | Process for isolation of hypolipemic effective substance |
EP0871720A2 (en) | 1995-06-07 | 1998-10-21 | Athena Neurosciences, Inc. | Beta-secretase, antibodies to beta-secretase, and assays for detecting beta-secretase inhibition |
KR100768381B1 (ko) | 1998-09-24 | 2007-10-18 | 파마시아 앤드 업존 캄파니 엘엘씨 | 알츠하이머병 세크레타제 |
MY138097A (en) | 2000-03-22 | 2009-04-30 | Du Pont | Insecticidal anthranilamides |
DE60116313T2 (de) | 2000-06-30 | 2006-08-31 | Elan Pharmaceuticals, Inc., San Francisco | Verbindungen zur behandlung der alzheimerischen krankheit |
US7196163B2 (en) | 2001-05-22 | 2007-03-27 | Merk & Co., Inc. | Assays using amyloid precursor proteins with modified β-secretase cleavage sites to monitor β-secretase activity |
US6982264B2 (en) | 2001-06-27 | 2006-01-03 | Elan Pharmaceuticals, Inc. | Substituted alcohols useful in treatment of Alzheimer's disease |
KR100713137B1 (ko) | 2001-06-28 | 2007-05-02 | 동화약품공업주식회사 | 신규의 2,4-디플루오로벤즈아미드 유도체 |
EP1406617A1 (en) | 2001-07-10 | 2004-04-14 | Elan Pharmaceuticals, Inc. | Diaminediols for the treatment of alzheimer's disease |
CA2453447A1 (en) | 2001-07-10 | 2003-01-23 | Elan Pharmaceuticals, Inc. | Alpha-hydroxyamide statine derivatives for the treatment of alzheimer's disease |
US20030109559A1 (en) | 2001-07-11 | 2003-06-12 | Andrea Gailunas | N-(3-amino-2-hydroxy-propyl)substituted alkylamide compounds |
AU2002343483A1 (en) | 2001-10-04 | 2003-04-14 | Elan Pharmaceuticals, Inc. | Hydroxypropylamines |
AU2002335794A1 (en) | 2001-10-05 | 2003-04-22 | Elan Pharmaceuticals, Inc | Allylamides useful in the treatment of alzheimer's disease |
MXPA04004079A (es) | 2001-10-29 | 2005-07-05 | Pharmacia & Upjohn Co Llc | Amidas hidroxi sustituidas para tratamiento de enfermedad de alzheimer. |
OA12846A (en) | 2001-11-08 | 2006-09-15 | Elan Pharm Inc | N,N'-substituted-1,3-diamino-2-hydroxypropane derivatives. |
TW200304374A (en) | 2001-11-30 | 2003-10-01 | Smithkline Beecham Plc | Novel compounds |
US7312360B2 (en) | 2001-12-06 | 2007-12-25 | Elan Pharmaceuticals, Inc. | Substituted hydroxyethylamines |
US6962934B2 (en) | 2002-01-04 | 2005-11-08 | Elan Pharmaceuticals, Inc. | Substituted amino carboxamides for the treatment of Alzheimer's disease |
JP2005526714A (ja) | 2002-01-17 | 2005-09-08 | ニューロジェン・コーポレーション | カプサイシンのモジュレーターとしての置換キナゾリン−4−イルアミン類縁体 |
US7115652B2 (en) | 2002-06-17 | 2006-10-03 | Sunesis Pharmaceuticals, Inc. | Aspartyl protease inhibitors |
CA2489095A1 (en) | 2002-06-17 | 2003-12-24 | Sunesis Pharmaceuticals, Inc. | Aspartyl protease inhibitors |
BR0312439A (pt) | 2002-06-20 | 2005-05-10 | Pharmacia & Upjohn Co Llc | Processo para preparação de derivados de ácido 5-(1,3-oxazol-2-il)benzóico |
UY27967A1 (es) | 2002-09-10 | 2004-05-31 | Pfizer | Acetil 2-hindroxi-1,3-diaminoalcanos |
WO2004043916A1 (en) | 2002-11-12 | 2004-05-27 | Merck & Co., Inc. | Phenylcarboxamide beta-secretase inhibitors for the treatment of alzheimer's disease |
GB0228410D0 (en) | 2002-12-05 | 2003-01-08 | Glaxo Group Ltd | Novel Compounds |
US7371853B2 (en) | 2003-01-07 | 2008-05-13 | Merck & Co., Inc. | Macrocyclic β-secretase inhibitors for the treatment of Alzheimer's disease |
GB0305918D0 (en) | 2003-03-14 | 2003-04-23 | Glaxo Group Ltd | Novel compounds |
AU2004218871A1 (en) | 2003-03-14 | 2004-09-23 | Merck & Co. Inc. | Method for treating mild cognitive impairment and for preventing or delaying Alzheimer's disease |
PA8601001A1 (es) | 2003-04-21 | 2005-02-04 | Elan Pharm Inc | Fenacilo 2-hidroxi-3-diaminoalcanos |
CA2523232A1 (en) | 2003-04-21 | 2004-11-04 | Elan Pharmaceuticals, Inc. | (hetero) arylamide 2-hydroxy-3-diaminoalkanes for use in the treatment of alzheimer's disease |
CA2529994A1 (en) | 2003-06-30 | 2005-01-20 | Merck & Co., Inc. | N-alkyl phenylcarboxamide beta-secretase inhibitors for the treatment of alzheimer's disease |
US7348448B2 (en) | 2003-07-01 | 2008-03-25 | Merck & Co., Inc. | Phenylcarboxylate beta-secretase inhibitors for the treatment of alzheimer's disease |
US7763609B2 (en) | 2003-12-15 | 2010-07-27 | Schering Corporation | Heterocyclic aspartyl protease inhibitors |
US7700603B2 (en) | 2003-12-15 | 2010-04-20 | Schering Corporation | Heterocyclic aspartyl protease inhibitors |
US7592348B2 (en) | 2003-12-15 | 2009-09-22 | Schering Corporation | Heterocyclic aspartyl protease inhibitors |
CN101671307B (zh) | 2003-12-15 | 2014-05-14 | 默沙东公司 | 杂环天冬氨酰蛋白酶抑制剂 |
GB0402143D0 (en) | 2004-01-30 | 2004-03-03 | Smithkline Beecham Corp | Novel compounds |
EP1732906A4 (en) | 2004-03-30 | 2007-11-21 | Merck & Co Inc | 2-AMINOTHIAZOLE COMPOUNDS USEFUL AS ASPARTYLE-PROTEASE INHIBITORS |
TW200602045A (en) | 2004-06-16 | 2006-01-16 | Wyeth Corp | Amino-5, 5-diphenylimidazolone derivatives for the inhibition of β-secretase |
CN101084199A (zh) | 2004-10-15 | 2007-12-05 | 阿斯利康(瑞典)有限公司 | 取代的氨基化合物及其用途 |
EP1836208A2 (en) | 2005-01-14 | 2007-09-26 | Wyeth Incoporated | AMINO-IMIDAZOLONES FOR THE INHIBITION OF ß-SECRETASE |
BRPI0607094A2 (pt) | 2005-02-01 | 2009-08-04 | Wyeth Corp | composto da fórmula i; uso do composto para o tratamento de uma doença ou distúrbio associado à atividade excessiva de bace em um paciente que dele necessita; uso do composto para modular a atividade de bace; e composição farmacêutica |
US7759337B2 (en) | 2005-03-03 | 2010-07-20 | Amgen Inc. | Phthalazine compounds and methods of use |
WO2006111370A1 (en) | 2005-04-19 | 2006-10-26 | Epfl (Ecole Polytechnique Federale De Lausanne) | A method and device for removing echo in a multi-channel audio signal |
EP1896032B1 (en) | 2005-06-14 | 2012-10-31 | Merck Sharp & Dohme Corp. | The preparation and use of compounds as protease inhibitors |
CA2610617A1 (en) | 2005-06-14 | 2006-12-28 | Schering Corporation | The preparation and use of protease inhibitors |
EP1896467B1 (en) | 2005-06-16 | 2010-12-01 | Janssen Pharmaceutica NV | Tricyclic opioid modulators |
TW200738683A (en) | 2005-06-30 | 2007-10-16 | Wyeth Corp | Amino-5-(5-membered)heteroarylimidazolone compounds and the use thereof for β-secretase modulation |
ATE550338T1 (de) | 2005-07-18 | 2012-04-15 | Merck Sharp & Dohme | Spiropiperidininhibitoren von beta-secretase zur behandlung von alzheimer-krankheit |
TW200730523A (en) | 2005-07-29 | 2007-08-16 | Wyeth Corp | Cycloalkyl amino-hydantoin compounds and use thereof for β-secretase modulation |
WO2007028769A1 (en) | 2005-09-05 | 2007-03-15 | Neurosearch A/S | Monoamine neurotransmitter re-uptake inhibitor for neuroprotection |
EP2256107A1 (en) | 2005-09-26 | 2010-12-01 | Wyeth LLC | Amino-5-[4-(difluoromethoxy)phenyl]-5-phenylimidazolone compounds as inhibitors of the beta-secretase (BACE) |
ES2572263T3 (es) | 2005-10-25 | 2016-05-31 | Shionogi & Co | Derivados de dihidrooxazina y tetrahidropirimidina como inhibidores de BACE 1 |
WO2007100536A1 (en) | 2006-02-24 | 2007-09-07 | Wyeth | DIHYDROSPIRO[DIBENZO[A,D][7]ANNULENE-5,4'-IMIDAZOL] COMPOUNDS FOR THE INHIBITION OF β-SECRETASE |
US20090099217A1 (en) | 2006-04-05 | 2009-04-16 | Astex Therapeutics Ltd. | 2-Aminopyrimidin-4-Ones And Their Use For Treating Or Preventing Alpha Beta-Related Pathologies |
TW200808751A (en) | 2006-04-13 | 2008-02-16 | Astrazeneca Ab | New compounds |
EP2032542A2 (en) | 2006-06-12 | 2009-03-11 | Schering Corporation | Heterocyclic aspartyl protease inhibitors |
TW200815447A (en) | 2006-06-14 | 2008-04-01 | Astrazeneca Ab | Novel compounds IV |
TW200815349A (en) | 2006-06-22 | 2008-04-01 | Astrazeneca Ab | New compounds |
AU2007285735A1 (en) | 2006-08-16 | 2008-02-21 | 4Cs Ag | Tetrahydrobenzothiophene derivatives |
WO2008054698A2 (en) | 2006-10-30 | 2008-05-08 | Merck & Co., Inc. | Spiropiperidine beta-secretase inhibitors for the treatment of alzheimer's disease |
TW200831091A (en) | 2006-12-20 | 2008-08-01 | Astrazeneca Ab | New compounds |
TW200831484A (en) | 2006-12-20 | 2008-08-01 | Astrazeneca Ab | New compounds |
EP2114906B1 (en) | 2007-02-02 | 2014-08-06 | F. Hoffmann-La Roche AG | 2-aminooxazolines as taar1 ligands for cns disorders |
PE20081791A1 (es) | 2007-02-28 | 2009-02-07 | Eisai Randd Man Co Ltd | Dos derivados ciclicos de oxomorfolina |
CL2008000791A1 (es) | 2007-03-23 | 2008-05-30 | Wyeth Corp | Compuestos derivados de 2-amino-5-(4-difluorometoxi-fenil)-5-fenil-imidazolidin-4-ona; composicion farmaceutica que comprende a dichos compuestos; y su uso en el tratamiento de una enfermedad asociada con la actividad bace excesiva, tales como enferm |
ES2476605T3 (es) | 2007-04-24 | 2014-07-15 | Shionogi & Co., Ltd. | Derivados de aminohidrotiazina sustituidos con grupos cíclicos |
JP5383483B2 (ja) | 2007-04-24 | 2014-01-08 | 塩野義製薬株式会社 | アルツハイマー症治療用医薬組成物 |
TW200902503A (en) | 2007-05-15 | 2009-01-16 | Astrazeneca Ab | New compounds |
US8158620B2 (en) | 2008-01-18 | 2012-04-17 | Eisai R&D Management Co., Ltd. | Fused aminodihydrothiazine derivatives |
MX2010008347A (es) | 2008-02-18 | 2010-11-12 | Hoffmann La Roche | Derivados de 4,5-dihidro-oxazol-2-ilamina. |
AU2009239536C1 (en) | 2008-04-22 | 2012-12-13 | Merck Sharp & Dohme Corp. | Phenyl-substituted 2-imino-3-methyl pyrrolo pyrimidinone compounds as BACE-1 inhibitors, compositions, and their use |
TWI431004B (zh) | 2008-05-02 | 2014-03-21 | Lilly Co Eli | Bace抑制劑 |
CN102119161B (zh) | 2008-06-13 | 2015-07-08 | 盐野义制药株式会社 | 具有β分泌酶抑制作用的含硫杂环衍生物 |
CN102083805A (zh) | 2008-07-24 | 2011-06-01 | 弗·哈夫曼-拉罗切有限公司 | 4,5-二氢-唑-2-基衍生物 |
MY148558A (en) | 2008-09-11 | 2013-04-30 | Amgen Inc | Spiro-tetracyclic ring compounds as betasecretase modulators and methods of use |
-
2011
- 2011-03-14 CA CA2791281A patent/CA2791281A1/en not_active Abandoned
- 2011-03-14 WO PCT/US2011/028417 patent/WO2011115938A1/en active Application Filing
- 2011-03-14 EP EP11710372A patent/EP2547685A1/en not_active Withdrawn
- 2011-03-14 MX MX2012010658A patent/MX2012010658A/es not_active Application Discontinuation
- 2011-03-14 JP JP2013500141A patent/JP2013522305A/ja not_active Withdrawn
- 2011-03-14 US US13/047,734 patent/US8883782B2/en active Active
- 2011-03-14 AU AU2011227511A patent/AU2011227511B2/en not_active Ceased
- 2011-03-15 UY UY0001033277A patent/UY33277A/es not_active Application Discontinuation
- 2011-03-15 TW TW100108803A patent/TW201144322A/zh unknown
- 2011-03-15 AR ARP110100822A patent/AR080524A1/es not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
MX2012010658A (es) | 2012-12-05 |
AU2011227511B2 (en) | 2014-02-20 |
AU2011227511A1 (en) | 2012-09-20 |
WO2011115938A1 (en) | 2011-09-22 |
EP2547685A1 (en) | 2013-01-23 |
JP2013522305A (ja) | 2013-06-13 |
US8883782B2 (en) | 2014-11-11 |
AR080524A1 (es) | 2012-04-11 |
US20110251190A1 (en) | 2011-10-13 |
CA2791281A1 (en) | 2011-09-22 |
TW201144322A (en) | 2011-12-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
UY33277A (es) | Compuestos de anillo espiro-tetraciclico como moduladores de beta-secretasa y métodos de uso | |
CL2012001605A1 (es) | Compuestos derivados de quinolina-2-carboxamida, moduladores alostericos positivos del receptor muscarino m1; composicion farmaceutica que comprende al compuesto; y su uso en la preparacion de medicamentos para el tratamiento de enfermedades tales como alzheimer, trastornos del dolor o del sueño. | |
CR20120591A (es) | Derivados de aminopirimidina como moduladores de la lrrk2 | |
BR112015020389A2 (pt) | compostos carbazol úteis como inibidores de bromodomínio | |
ECSP13013048A (es) | Spiro-[1,3]-oxacinas y spiro-[1,4]-oxacepinas como inhibidores | |
CR20140567A (es) | Formulaciones y métodos para la administración vaginal de antiprogestinas | |
CO7101245A2 (es) | Compuestos de benzaldehído sustituidos y métodos para su uso en incrementar la oxigenación del tejido | |
DOP2012000299A (es) | 5-fluoro-1h-pirazolopiridinas sustituidas y su uso | |
BR112015010663A2 (pt) | formas de dosagem de ruxolitinib de liberação sustentada | |
DOP2014000008A (es) | 4-imidazopiridazina-1-il-benzamidas y 4-imidazotriazina-1-il-benzamidas como inhibidores de btk | |
CL2014001752A1 (es) | Compuestos biciclicos sustituidos; composicion farmaceutica que los comprende; y uso en el tratamiento de enfermedades tales como cancer, alzheimer, sida, entre otras. | |
CL2012002497A1 (es) | Compuestos derivados de imidazopirimidina,sustituidos, inhibidores de la pde10a; procedimiento de preparacion; composicion farmaceutica; y su uso para el tratamiento o prevencion de trastornos psicoticos, esquizofrenia, enfermedad de parkinson, esclerosis multiple, entre otras. | |
DOP2013000104A (es) | Antagonistas de mdm2 de espiro-oxindol | |
BR112014030165A2 (pt) | inibidores do bromodomínio de benzo [c] isoxazoloazepina e seu uso | |
UY33863A (es) | Metodos y medicamentos para el tratamiento de la enfermedad de alzheimer | |
CR20130588A (es) | Halogenoalquil-1,3-oxazinas como inhibidores de la bace1 y/o bace 2 | |
CL2012001673A1 (es) | Compuestos derivados de benzamida sustituidos, como moduladores de taar; procedimiento de preparación; composición farmacéutica; y su uso en el tratamiento de la depresión, trastornos de ansiedad, trastorno bipolar, esquizofrenia, epilepsia, migraña, enfermedad de alzheimer, trastornos metabolicos, entre otras. | |
BR112013004766A2 (pt) | 2-amino-quinolina-3-carboxamidas substituídas como moduladores de kcnq2/3 | |
CL2011002766A1 (es) | Compuestos derivados de carboxamida, inhibidores de calpaina; composicion farmaceutica que los comprende; y su uso en el tratamiento de enfermedades neurodegenerativas, alzahimer, dolor, entre otras. | |
CL2012002175A1 (es) | Composicion farmaceutica oral de liberacion prolongada que comprende un agente activo de fracciones de propargilamina y aminoindano; metodo de preparacion; uso en el tratamiento de enfermedades neurodegenerativas o lesiones en el sistema nervioso tales como parkinson o alzheimer, un accidente cerebrovascular o lesion traumatica cerebral. | |
CL2014001838A1 (es) | Compuestos derivados de fluormetil-5,6-dihidro-4h-[1,3]oxazin-2-ilamina, como inhibidores de la bace1; su proceso de obtencion; composicion farmaceutica que los contiene; y su uso para el tratamiento terapeutico y/o profilactico de la enfermedad de alzheimer, esclerosis lateral amiotrofica, cancer, enfermedades cardiovasculares y enfermedades gastrointestinales, entre otras. | |
UY35276A (es) | Nuevos compuestos que inhiben la actividad de Lp-PLA2 | |
UY33276A (es) | Compuestos de amino-oxazinas y amino-dihidrotiazina como moduladores de beta-secretasa y métodos de uso | |
CL2008001820A1 (es) | Compuestos derivados de aril-isoxasol-imidazol; procedimiento de preparacion; composicion farmaceutica que los contiene; y uso en la preparacion de medicamentos utiles en el tratamiento de trastornos cognitivos y enfermedades relacionadas con alzheimer. | |
UA109260C2 (uk) | Хромонові похідні, спосіб їх одержання та їх терапевтичні застосування |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
109 | Application deemed to be withdrawn |
Effective date: 20191217 |